New Consortium Will Optimaze Drug Discovery

  • Author: ChemistryViews
  • Published: 30 November 2012
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Bayer HealthCare
  • Associated Suppliers: Bayer AG, Leverkusen, Germany
thumbnail image: New Consortium Will Optimaze Drug Discovery

The newly founded international consortium K4DD (Kinetics for Drug Discovery) will focus on optimizing binding kinetics for drug candidates with the goal of improving drug design. Dr. Anke Müller-Fahrnow, Vice President and Head of Lead Discovery Berlin, Bayer HealthCare Global Drug Discovery, is the coordinator and Ad P. IJzerman, professor of medicinal chemistry at the Leiden/Amsterdam Center for Drug Research of Leiden University, The Netherlands, is the academic lead of the K4DD consortium. The five-year project consists of pharma companies, universities, knowledge institutes and smaller companies from all over Europe.

Financially it is supported with 20 million Euro by Europe’s Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in health.


Compound binding characteristics to its molecular target (binding kinetics) is of high importance for eventual clinical drug efficacy. However, despite the efforts in finding high-affinity and selective compounds, attrition rates of candidate drugs are still disappointingly high. Almost 90 % of clinical drug candidates that enter clinical trials still fail.
The goal of this project is that kinetic aspects of drug-target interactions can routinely be studied in robust and accessible assays for all main drug target classes within and outside the consortium. ‘Kinotypic’ knowledge should guide the identification and optimization process of drug candidates in the early phases of drug discovery in the future.


Article Views: 2091

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH